You are viewing: China Recombinant Proteins Market analysis
Part of: Recombinant Proteins Market (Global)

The China Recombinant Proteins Market was valued at $55.7 Million in 2023 and projected to reach to $87.1 Million by 2028, representing a compound annual growth rate of 9.3%. China's recombinant proteins market is positioned for accelerated growth through 2028, driven by increasing healthcare spending and the rising prevalence of chronic diseases requiring advanced biopharmaceutical interventions.

China Recombinant Proteins Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Recombinant Proteins Market Trends and Insights

  • This robust expansion in China is driven by increasing demand for biopharmaceuticals, rising healthcare expenditure, and growing adoption of recombinant protein therapeutics across therapeutic areas including oncology, immunology, and rare diseases.
  • China's position as a major hub for biomanufacturing and its supportive regulatory environment continue to accelerate market penetration. The recombinant proteins market in China is benefiting from substantial investments in research and development, coupled with government initiatives to strengthen the domestic biotech ecosystem.
  • China's pharmaceutical companies are increasingly developing and commercializing recombinant protein-based treatments, reducing reliance on imports and creating competitive pricing advantages.
  • The forecast period through 2028 anticipates sustained growth in China as healthcare modernization and patient access programs expand the addressable market for advanced protein therapeutics..

Key Market Statistics

  • CAGR (2023-2028) 9.3% CAGR
  • Market Size, 2023 ~USD 55.7 Million
  • Forecast, 2028 ~USD 87.1 Million
  • Country China

China Recombinant Proteins Market Overview

Market Valuation Growth :

China's recombinant proteins market reached $55.7 million in 2023 and is expected to grow to $87.1 million by 2028, demonstrating strong market momentum with a 9.3% CAGR, outpacing the global average of 7.2%.

Biopharmaceutical Demand Surge :

Increasing adoption of recombinant protein therapeutics across oncology, immunology, and other therapeutic areas is driving market expansion as Chinese healthcare providers seek advanced treatment options.

Healthcare Investment Acceleration :

Rising healthcare expenditure in China, coupled with government support for biopharmaceutical innovation, is creating favorable conditions for recombinant protein market development and commercialization.

Therapeutic Area Diversification :

Expanding applications of recombinant proteins across multiple therapeutic domains including oncology and immunotherapy are broadening market opportunities and driving sustained growth in China.

China Recombinant Proteins Market Dynamics

  • The market's 9.3% CAGR reflects strong demand for innovative protein-based therapeutics and growing adoption among Chinese healthcare institutions. Government initiatives supporting domestic biopharmaceutical development, combined with improving regulatory frameworks and manufacturing capabilities, will further strengthen market expansion.
  • As China continues to establish itself as a global biopharmaceutical hub, recombinant protein therapeutics will play an increasingly critical role in addressing unmet medical needs across oncology, immunology, and other therapeutic areas..

Market Ecosystem

logo-mobile

RECOMBINANT PROTEINS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Recombinant cytokines and growth factors from its Gibco, Invitrogen, and PeproTech brands are used in cell culture, drug discovery, immunology research, stem cell expansion, and cell therapy manufacturing. Its GMP-grade proteins support the production of cell-based therapies. Supports reproducible cell culture and immune-cell expansion | Enables research-to-manufacturing workflows | Supports clinical manufacturing requirements through GMP-grade proteins.
company logo
Merck provides recombinant protein expression and process-development technologies for biopharmaceutical applications. Its CHOZN expression platform and associated process-development services support the development and scale-up of recombinant proteins and other biologics. Supports high-producing cell-line development | Facilitates process optimization and scale-up | Helps improve manufacturing productivity and consistency.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • China's recombinant proteins market is projected to grow from $55.7M (2023) to $87.1M (2028) at a 9.3% CAGR.
    • China's biomanufacturing capabilities and supportive regulatory environment position it as a key growth driver in Asia Pacific.
    • Rising healthcare expenditure and demand for advanced therapeutics are accelerating recombinant protein adoption across China.
    • China's domestic biotech companies are increasingly developing recombinant protein treatments, reducing import dependency and enhancing market competition.

    Recombinant Proteins Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment INTERFERONS (IFNS) (Type)
    Forecast Period 2023-2028
    Growth Rate CAGR of 7.2% from 2023 to 2028
    Largest Segment PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User)
    Market Size Base Year (Billions) ~USD 2.26 (2023)
    Revenue Forecast (Billions) ~USD 3.2 (2028)
    Segments Covered Product, Type, Application, Host Cell, End User

    China Recombinant Proteins Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product

    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Other Recombinant Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins

    By Type

    • Academic Research
    • Biologics
    • Biotechnology Research
    • Cell & Gene Therapy
    • Interferons (Ifns)
    • Interleukins (Ils)
    • Other Growth Factors & Chemokines
    • Vaccines

    By Application

    • Biopharmaceutical Production
    • Diagnostics
    • Drug Discovery & Development
    • Other Applications
    • Research

    By Host Cell

    • Bacterial Cells
    • Insect Cells
    • Mammalian Systems
    • Other Cell Hosts
    • Other Host Cells
    • Yeast & Fungi

    By End User

    • Academic Research Institutes
    • Biotechnology Companies
    • Contract Research Organizations
    • Other End Users
    • Pharmaceutical & Biopharmaceutical Companies

    CHINA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028

    Segment20212022202320242025202620272028CAGR (%)
    ACADEMIC RESEARCH INSTITUTES34.135.237.740.64447.852.2578.6
    BIOTECHNOLOGY COMPANIES23.924.726.428.430.733.336.339.68.5
    CONTRACT RESEARCH ORGANIZATIONS12.61313.814.81617.318.820.58.2
    OTHER END USERS88.28.69.19.810.511.212.17
    PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES6769.474.480.387.194.8103.6113.38.8
    TOTAL145.61150.4160.84173.32187.57203.71222.19242.578.6

    Target Audience

    • Biopharmaceutical Companies : Manufacturers and developers of recombinant protein therapeutics need China-specific market data to assess market opportunity, plan product launches, and allocate R&D resources effectively.
    • Healthcare Investment Firms : Private equity and venture capital investors require detailed China market analysis to evaluate investment opportunities in recombinant protein companies and biopharmaceutical ventures.
    • Market Entry Consultants : Strategy and consulting firms advising clients on China expansion need localized market intelligence to develop go-to-market strategies and competitive positioning recommendations.
    • Healthcare Policy Makers : Government agencies and regulatory bodies in China benefit from market data to inform healthcare policy, biopharmaceutical incentives, and therapeutic priority-setting decisions.
    • Contract Research Organizations : CROs and clinical research providers need China market insights to identify growth opportunities, understand therapeutic demand, and align service offerings with market needs.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for China's recombinant proteins market with verified 9.3% CAGR projections through 2028, enabling accurate financial forecasting and investment decision-making.
    • Competitive Positioning Intelligence : Understand China-specific market dynamics, therapeutic area adoption rates, and regional growth drivers to benchmark competitive positioning against local and international biopharmaceutical players.
    • Strategic Market Entry Planning : Access detailed insights on China's healthcare expenditure trends, regulatory environment, and recombinant protein adoption patterns to inform market entry strategies and localization approaches.
    • Investment & Expansion Decisions : Leverage comprehensive China market data to justify capital allocation, identify high-growth therapeutic segments, and prioritize geographic expansion within Asia's largest biopharmaceutical market.
    • Stakeholder Communication : Present credible, data-backed market projections to investors, board members, and partners regarding China's recombinant protein market opportunity and long-term growth potential.

    Frequently asked questions

    What is the current size of China's recombinant proteins market?

    China's recombinant proteins market was valued at $55.7 million in 2023 and is expected to reach $87.1 million by 2028.

    What is the projected growth rate for recombinant proteins in China?

    China's recombinant proteins market is expected to grow at a compound annual growth rate (CAGR) of 9.3% from 2023 to 2028.

    What factors are driving growth in China's recombinant proteins market?

    Key drivers include rising healthcare expenditure, increasing demand for biopharmaceuticals, government support for biotech development, and expanding patient access programs across China.

    How does China's recombinant proteins market compare to global trends?

    China's 9.3% CAGR outpaces the global market growth rate of 7.2%, reflecting stronger regional demand and investment in biopharmaceutical innovation.

    What therapeutic areas are driving recombinant protein demand in China?

    Primary therapeutic areas include oncology, immunology, and rare diseases, where recombinant protein therapeutics are increasingly adopted across China's healthcare system.

    RESEARCH METHODOLOGY

    This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global recombinant proteins market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.

    Secondary Research

    The secondary sources referred to for this research study include publications from government sources,such as the World Health Organization, The Antibody Society,Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC),National Center for Biotechnology Information (NCBI), American Medical Association (AMA), RecombinantAntibody Network (RAN), National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), and the Institute for Molecular Medicine, corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, professional associations, and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

    Recombinant Protein Market 
 Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The top-down and bottom-up approaches were used to estimate & validate the total size of the recombinant proteins market. These methods were also used extensively to estimate the size of various market segments.

    Recombinant Protein Market Top Down and Bottom Up Approach

    Data Triangulation

    After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.

    Market Definition

    Recombinant proteins are manipulated proteins generated by recombinant DNA technology that modifies gene sequences. These are formed by transfecting foreign genes into a host cell. Recombinant proteins are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses. This market includes recombinant protein products, including growth factors, cytokines, recombinant enzymes, structural proteins, and membrane proteins.

    Key Stakeholders

    • Pharmaceutical & Biopharmaceutical Companies
    • Biotechnology Companies
    • Life Sciences Companies
    • Academic Research Institutes
    • Government Institutes
    • Private Research Firms
    • Contract Research Organizations (CROs)
    • Third-party Suppliers, Direct Suppliers, Distributors, and Channel Partners
    • Venture Capitalists and Investors
    • Market Research and Consulting Firms

    Report Objectives

    • To define, describe, and forecast the recombinant proteins market based on product, host cell, application, and end user
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall recombinant proteins market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders  
    • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To strategically profile the key players in the recombinant proteins market and comprehensively analyze their core competencies and market rankings
    • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the recombinant proteins market
    • To benchmark players within the recombinant proteins market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe recombinant proteins market, by country
    • Further breakdown of the Rest of Asia Pacific recombinant proteins market, by country
    • Further breakdown of the Rest of Latin America recombinant proteins market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

     

    Get the Full Recombinant Proteins Market Report

    Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status